

Cover Story
ClinicalReal-world Evidence
By Matthew Bin Han Ong
A novel study led by Friends of Cancer Research is providing evidence that tumor response rates can be assessed across real-world data sets, bringing regulators one step closer to potentially building a framework for pre-market evaluation of cancer drugs and post-market tracking of drug performance based on real-world endpoints.
In Brief


Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for October 2023
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eight
NCI to remain intact, but its finances are uncertain; FDA is spared big cuts - John Burklow replaced by Seana Cranston as NIH chief of staff
- In the Headlines: What’s in Trump’s draft budget?
- NCI summarizes changes to the CCSG NOFO
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - AACR announces 2025 Scientific Achievement Award recipients